Table 1.

Features of patients with CAPS analyzed for NLRP3 mosaicism. All patients are characterized by increment of inflammatory markers at clinical diagnosis. No patients showed AA amyloidosis.

Patient No.1234567891011121314
SexFMFMFFFMMFMMMF
PhenotypeMWSCINCAMWSFCASMWSCINCACINCAMWSFCASMWSMWS*MWSMWSMWS
Birth yr20071971200119982000199519852001197319821986200119961976
Age at onset2 mos2 mos10 mos2 yrs11 yrs3 mosbirth10.5 yrs< 1 yr2 yrs2 yrs5 yrs3 yrs5 yrs
Age at referral18 mos30 yrs5 yrs12 yrs12 yrs15 mos8 yrs12 yrs37 yrs31 yrs25 yrs8 yrs17 yrs34 yrs
FeverYesYesYesYesYesYesYesYesYesYesYesYesYesYes
Urticaria-like rashYesYesYesYesYesYesYesYesYesYesYesYes
ArthritisYesYesArthralgiasYesYesYesYesYesYesYesYes
Typical faciesYesYes
HeadacheYesYesYes
Mental retardationYes
Aseptic meningitisYes
PapilloedemaYesYes
Hearing lossYesYesYes§Yes
Bone dysplasiaYesYesYes
Growth delayYesYesYesYes
Uveitis/conjunctivitisYesYesYes
Trigger by coldYesYesYesYes
Anti-IL-1 treatmentYesYesYesYesYesYesYesYesYesYesYes
  • § Mild (audiometry).

  • * Mild phenotype. CAPS: cryopyrin-associated periodic syndrome; MWS: Muckle-Wells syndrome; CINCA: chronic infantile neurological cutaneous and articular syndrome; FCAS: familial cold autoinflammatory syndrome; IL: interleukin.